Floatz logo

Ivonescimab

KRAS G12C

Cancer Institute and Hospital, Chinese Academy of Medical Sciencesmonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
Adagrasib
Ryan Gentzler, MD
Phase 2CCC
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Opnurasib
Maastricht University Medical Center
Phase 2CCC
Fulzerasib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2CCC

View all 23 →

Same molecule, other indications

Ivonescimab is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
64 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →